Steven Acosta, MD
Emergency Medicine · Las Cruces, NMNPI 1861531865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Bayer at 30.2% of the total. Reporting peaked in 2021 at $118 and has fallen 57.9% since, to $50 in 2024. Among emergency medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$75
- Johnson & Johnson$50
- Abbott$43
- Boehringer Ingelheim$21
- GSK$18
- Novartis$14
- plus $27 from 2 others
Across 32 payments — averaging $5732.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taro Pharmaceuticals USA, Inc.$134K
- Teva Pharmaceuticals USA, Inc.$38K
- Journey Medical Corporation$12K
What the payments were for
- Food & beverage$247100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 1 | $75 |
| Johnson & Johnson | 1 | $50 |
| Abbott | 2 | $43 |
| Boehringer Ingelheim | 1 | $21 |
| GSK | 1 | $18 |
| Novartis | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
How this compares
$247 in reported general payments places this provider in the 90th percentile of 367 emergency medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 17 | $28,643 |
| OzempicSemaglutide | 14 | $19,959 |
| EliquisApixaban | 23 | $7,345 |
| SynthroidLevothyroxine Sodium | 21 | $1,684 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,007 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 43 | $894 |
| Levothyroxine Sodium | 69 | $799 |
| Losartan Potassium | 51 | $631 |
| Lisinopril | 76 | $609 |
| Atorvastatin Calcium | 50 | $608 |
| Rosuvastatin Calcium | 38 | $606 |
| Amlodipine Besylate | 65 | $601 |
| Omeprazole | 25 | $535 |
| Memantine Hcl | 45 | $524 |
| Doxycycline Hyclate | 32 | $506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $21 | $28,64317 claims |
| Novo NordiskOzempic | $13 | $19,95914 claims |
| Lilly USA, LLCOlanzapine | $14 | $8112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 emergency medicine providers in New Mexico.
Other emergency medicine in Las Cruces
- Michael LaraLas Cruces$1K
- Dorothy HabratRio Rancho$11K
- Jonathan MarinaroAlbuquerque$8K
- Julie KanterAlbuquerque$8K
- James CottonAlbuquerque$7K
- Ethan SimsAlbuquerque$4K
- Robert AlundayAlbuquerque$4K
- David SklarAlbuquerque$3K
- Marshall BacaArtesia$1K
- Tammy Baillio JonesAlbuquerque$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.